OXBDF (Oxford BioMedica) Total Payout Ratio: 1.80 (As of Jul. 15, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OXBDF Oxford BioMedica PLC OXBDF
72 GF Score
Price $7.99
GF Value $7.16
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Oxford BioMedica Total Payout Ratio?

Oxford BioMedica OXBDF 72 Total Payout Ratio is 1.80 as of Jul. 15, 2026. GuruFocus rates OXBDF with a GF Score™ of 72/100 and a GF Value™ of $7.16 (Modestly Overvalued). The stock has 5 warning signs investors should review.

Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income.

Oxford BioMedica's current Total Payout Ratio is 1.80.

Oxford BioMedica Total Payout Ratio Related Terms

Oxford BioMedica Total Payout Ratio Historical Data

* Premium members only.

The historical data trend for Oxford BioMedica's Total Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oxford BioMedica Total Payout Ratio Chart

Oxford BioMedica Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Payout Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.60 1.74 0.00 0.37 1.82

Oxford BioMedica Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Payout Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.48 0.05 0.00 9.82

OXBDF vs VRTX, REGN, ALNY: Total Payout Ratio Comparison

For the Biotechnology subindustry, Oxford BioMedica's Total Payout Ratio, along with its competitors' market caps and Total Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Oxford BioMedica Total Payout Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oxford BioMedica's Total Payout Ratio distribution charts can be found below:

* The bar in red indicates where Oxford BioMedica's Total Payout Ratio falls into.


OXBDF
72GF Score
Oxford BioMedica PLC OXBDF
Total Payout Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Oxford BioMedica Total Payout Ratio Calculation

Total Payout Ratio is a measurement showing the proportion of earnings a company pays shareholders in the form of dividends and net stock repurchases.

Oxford BioMedica's Total Payout Ratio for the fiscal year that ended in Dec. 2025 is calculated as

Total Payout Ratio=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) / Net Income
=- (0 + 77.722 + 0) / -42.752
=1.82

Oxford BioMedica's Total Payout Ratio for the quarter that ended in Dec. 2025 is calculated as

Total Payout Ratio=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) / Net Income
=- (0 + 77.596 + 0) / -7.906
=9.81

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Payout Ratio →
What does a Total Payout Ratio of 1.80 mean?
Oxford BioMedica (OXBDF) has a Total Payout Ratio of 1.80 as of Jul. 15, 2026. Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income. View historical data on Oxford BioMedica and its competitors.
Is Oxford BioMedica's Total Payout Ratio too high?
Oxford BioMedica's current Total Payout Ratio is 1.80. Overall, Oxford BioMedica has a GF Score™ of 72/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Oxford BioMedica's Total Payout Ratio compare to VRTX and REGN?
Oxford BioMedica's Total Payout Ratio of 1.80 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Payout Ratio for a Biotechnology company?
A good Total Payout Ratio depends on the Biotechnology industry context. However, Total Payout Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Payout Ratio mean?
A high Total Payout Ratio can signal that a stock is expensive relative to its fundamentals. Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income. View historical data on Oxford BioMedica and its competitors. Oxford BioMedica's current Total Payout Ratio is 1.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oxford BioMedica stock overvalued right now?
Based on GuruFocus' analysis, Oxford BioMedica (OXBDF) is currently considered Modestly Overvalued. The stock's GF Value™ is $7.16, compared to a current price of $7.99 — trading 11.6% above its estimated fair value. The current Total Payout Ratio is 1.80. Oxford BioMedica's overall GF Score™ is 72/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Payout Ratio calculated?
Total Payout Ratio is calculated from a company's financial statements. For Oxford BioMedica (OXBDF), the current Total Payout Ratio is 1.80 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Oxford BioMedica (OXBDF) Overvalued in 2026?

Based on GuruFocus' analysis, Oxford BioMedica stock appears to be overvalued. The current stock price of $7.99 is trading 11.6% above its estimated GF Value™ of $7.16. GuruFocus considers Oxford BioMedica to be Modestly Overvalued.

Key valuation signals for OXBDF:

  • Total Payout Ratio: 1.80
  • GF Value™: $7.16 vs. price of $7.99 (11.6% above fair value)
  • GF Score™: 72/100 with 5 warning signs

No single metric tells the full story. See the OXBDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Oxford BioMedica Business Description

Other Exchanges OXBl:UKOXB:UKOXO:Germany
Address Transport Way, Windrush Court, Oxford, GBR, OX4 6LT
Oxford BioMedica PLC is a contract development and manufacturing organization (CDMO) focused on cell and gene therapy. The company specializes in viral vector development and manufacturing for cell and gene therapy, with expertise in lentivirus, adeno-associated virus (AAV), adenovirus, and other viral vector types. Geographically, it derives maximum revenue from the United States, and the rest from Europe, the UK, and the Rest of the world.
72GF Score

Get the complete analysis for OXBDF

Total Payout Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.99
Price
$7.16
GF Value